Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.
Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA.
J Appl Clin Med Phys. 2021 Aug;22(8):175-190. doi: 10.1002/acm2.13343. Epub 2021 Jul 26.
The aim of this report is to present the root cause analysis on failed patient-specific quality assurance (QA) measurements of pencil beam scanning (PBS) protons; referred to as PBS-QA measurement. A criterion to fail a PBS-QA measurement is having a <95% passing rate in a 3.0%-3.0 mm gamma index analysis. Clinically, we use a two-dimensional (2D) gamma index analysis to obtain the passing rate. The IBA MatriXX PT 2D detection array with finite size ionization chamber was utilized. A total of 2488 measurements performed in our PBS beamline were cataloged. The percentage of measurements for the sites of head/neck, breast, prostate, and other are 53.3%, 22.7%, 10.5%, and 13.5%, respectively. The measurements with a passing rate of 100 to >94%, 94 to >88%, and <88% were 93.6%, 5.6%, and 0.8%, respectively. The percentage of failed measurements with a <95% passing rate was 10.9%. After removed the user errors of either re-measurement or re-analysis, 8.1% became acceptable. We observed a feature of >3% per mm dose gradient with respect to depth on the failed measurements. We utilized a 2D/three-dimensional (3D) gamma index analysis toolkit to investigate the effect of depth dose gradient. By utilizing this 3D toolkit, 43.1% of the failed measurements were improved. A feature among measurements that remained sub-optimal after re-analysis was a sharp >3% per mm lateral dose gradient that may not be well handled using the detector size of 5.0 mm in-diameter. An analysis of the sampling of finite size detectors using one-dimensional (1D) error function showed a large dose deviation at locations of low-dose areas between two high-dose plateaus. User error, large depth dose gradient, and the effect of detector size are identified as root causes. With the mitigation of the root causes, the goals of patient-specific QA, specifically detecting actual deviation of beam delivery or identifying limitations of the dose calculation algorithm of the treatment planning system, can be directly related to failure of the PBS-QA measurements.
本报告旨在对笔形束扫描(PBS)质子的失败患者特定质量保证(QA)测量进行根本原因分析;称为 PBS-QA 测量。将通过在 3.0%-3.0 毫米伽马指数分析中获得小于 95%通过率的方法来判定 PBS-QA 测量失败。在临床中,我们使用二维(2D)伽马指数分析来获得通过率。我们使用有限大小电离室的 IBA MatriXX PT 2D 检测阵列。对我们 PBS 束线中的 2488 次测量进行了编目。头部/颈部、乳房、前列腺和其他部位的测量次数分别占 53.3%、22.7%、10.5%和 13.5%。通过率为 100%至>94%、94%至>88%和<88%的测量次数分别为 93.6%、5.6%和 0.8%。通过率小于 95%的失败测量次数占 10.9%。在去除重新测量或重新分析的用户误差后,8.1%的测量结果可以接受。我们观察到失败测量的深度剂量梯度超过了 3%/毫米。我们使用 2D/三维(3D)伽马指数分析工具包来研究深度剂量梯度的影响。通过使用这个 3D 工具包,43.1%的失败测量得到了改善。重新分析后仍然不理想的测量结果的一个特征是横向剂量梯度超过 3%/毫米,这可能无法使用直径为 5.0 毫米的探测器尺寸很好地处理。使用一维(1D)误差函数对有限大小探测器的采样进行分析,结果表明在两个高剂量平台之间的低剂量区域,剂量存在很大偏差。用户误差、大深度剂量梯度和探测器尺寸的影响被确定为根本原因。通过缓解这些根本原因,患者特定 QA 的目标,特别是检测束流输送的实际偏差或识别治疗计划系统的剂量计算算法的局限性,可以与 PBS-QA 测量的失败直接相关。